+0.8%
since Sep 17
The idea
I believe looking better is turning into routine spending, and GLP-1 drugs are accelerating it by creating millions of people who then want skin, face, and body fixes. So I own the whole chain: the drugmakers, the injectables and toxin makers, the devices and implants medspas buy, the supply distributor, and the beauty and telehealth platforms catching this demand. I keep the large caps as the anchor, size the smaller names so no single one can hurt the basket, and hold cash on the side.
What it owns
- Retailers and digital sellers of beauty and appearance products benefit as cosmetic treatment becomes mainstream and routine. · Hims & Hers HealthIt sells hair loss, skin, and weight loss treatment by phone, making appearance medicine as accessible as online shopping., Oddity TechIt sells beauty directly online through brands like Il Makiage, betting that the next generation buys appearance products digitally., e.l.f. BeautyIt takes market share in mass-market cosmetics by staying cheap and trending fast, showing what beauty looks like when it goes mainstream., Ulta BeautyIt is where mainstream America buys beauty, so its sales show whether appearance spending is truly becoming routine consumer behavior., Estée LauderIts prestige beauty portfolio benefits if cosmetic and appearance spending broadens globally and China's consumer demand recovers., LifeMDIts weight management program rides GLP-1 demand as a smaller alternative to larger telehealth platforms., Beauty Health CompanyIts Hydrafacial machines operate in medspas serving the post-weight-loss crowd, generating revenue from both equipment sales and regular consumable use.30%
- Medical devices tighten skin, restore volume, or improve appearance after weight loss or as standalone cosmetic procedures. · Align TechnologyIts Invisalign system straightens teeth as part of the routine appearance investment that adults now pursue throughout their lives., InModeIt makes radiofrequency devices medspas use to tighten loose skin without surgery, directly addressing what GLP-1 weight loss leaves behind., Establishment LabsIt makes Motiva breast implants, often restoring volume after significant weight loss, with the US market driving growth., Envista HoldingsIt sells dental implants and orthodontic supplies, providing the infrastructure behind cosmetic dentistry and smile treatments., Apyx MedicalIt makes Renuvion, a device surgeons use specifically to tighten skin after major weight loss, making it one of the purest plays on GLP-1 aftermath.23%
- Rapid weight loss driven by GLP-1 medications creates demand for the appearance fixes that follow throughout this take. · Eli LillyIts Zepbound and Mounjaro prescriptions are creating the wave of rapid weight loss that drives demand for appearance fixes throughout this take., Novo NordiskIts Ozempic and Wegovy are the other half of the GLP-1 duopoly creating the wave of patients who later spend on skin and body fixes.17%
- Botox, fillers, and toxin treatments address the skin deflation that fast weight loss leaves behind, with patients returning regularly. · AbbVieIt owns Botox and Juvederm, the standard treatments for skin deflation after fast weight loss, with patients returning every few months., EvolusIt sells Jeuveau, a cheaper Botox alternative aimed at younger price-sensitive patients making cosmetic treatment routine.15%
- Suppliers serve the medical and dental offices performing cosmetic procedures, benefiting from practice spending across all treatments. · Henry ScheinIt distributes supplies to dental and medical practices, earning revenue whenever offices performing cosmetic work restock.5%
- Cash10%